Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
US11472802B2 · kind B2 · utility
0Cited by
82References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 18, 2019 |
| Grant date | Oct 18, 2022 |
| Priority date | — |
| Expiry date | Jun 13, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/6561
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.